Accurate detection and quantitation of apoptotic events are key to further understand cellular mechanisms with a view to discovering novel drugs. This study describes a method for the immunocytochemical detection of the85kDa caspase-cleaved fragment of human PARP (amarker of apoptosis) in HeLa cells ...
ICIs in combination with agents that target other steps may be more effective, and PARP inhibitors belong to this kind of drugs with the ability to modulate tumor microenvironment. PARP inhibitors are agents targeting homologous recombination (HR) pathway. PARP inhibitors, such as olaparib and nira...
Cell lines, drugs and peptide receptor radionuclide therapy SSTR2 transfected A427 cells (A427–7) were grown as previously described39. Upon STR profiling analysis (Australian Genome Research Facility, Melbourne, Australia) this cell line matched (>90%) to another non-small cell lung cancer cell...
The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX...
Among lots of old and new drugs, PARP-inhibitors were not considered as possible option in the treatment of Covi-2 infection, being the latter able to induce the inflammatory and thrombotic cascades. Since PARP-inhibitors are able to reduce and block mechanisms leading to thrombosis and ...
, it is reasonable to speculate that the upregulation of PD-L1 by PARPi may render PARPi-treated cancer cells more resistant to T-cell killing, thus masking the beneficial effects of PARPi on TME, which also provides a rationale for the combination of PARPi with anti-PD-1/PD-L1 drugs...
However, there is currently a lack of evidence-based study to directly compare the effects of combination therapy with these two drugs. Therefore, this study aimed to compare the efficacy and safety of combination therapy with PARP inhibitors and antiangiogenic agents in women with OC using a ...
The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX...
The tumor xenograft models were established to evaluate the efficacy of drugs in vivo.#PARPi inhibited cell proliferation, promoted cell apoptosis, and induced S-phase cell cycle arrest in NKTCL cells. PARPi led to the accumulation of DNA damage by blocking DNA repair and DNA replication. ...
The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX...